# Karoly Toth

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/777599/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 58 papers | 3,170 citations | 185998 28 h-index | 168136 53 g-index |
| 60 all docs | 60 docs citations | 60 times ranked | 3044 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Adenovirus Vectors for Gene Therapy, Vaccination and Cancer Gene Therapy. Current Gene Therapy, 2014, 13, 421-433. | 0.9 | 411 |
| 2 | Forced degradation of Fas inhibits apoptosis in adenovirus-infected cells. Nature, 1998, 392, 726-730. | 13.7 | 196 |
| 3 | Tumor-Specific, Replication-Competent Adenovirus Vectors Overexpressing the Adenovirus Death Protein. Journal of Virology, 2000, 74, 6147-6155. | 1.5 | 190 |
| 4 | Immune responses to adenoviruses: viral evasion mechanisms and their implications for the clinic. Current Opinion in Immunology, 1999, 11, 380-386. | 2.4 | 179 |
| 5 | miRNA-29b Suppresses Prostate Cancer Metastasis by Regulating Epithelialâ€“Mesenchymal Transition Signaling. Molecular Cancer Therapeutics, 2012, 11, 1166-1173. | 1.9 | 173 |
| 6 | FUNCTIONS AND MECHANISMS OF ACTION OF THE ADENOVIRUS E3 PROTEINS. International Reviews of Immunology, 2004, 23, 75-111. | 1.5 | 160 |
| 7 | Syrian Hamster as a Permissive Immunocompetent Animal Model for the Study of Oncolytic Adenovirus Vectors. Cancer Research, 2006, 66, 1270-1276. | 0.4 | 148 |
| 8 | Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 7293-7297. | 3.3 | 124 |
| 9 | Tissue-Specific, Tumor-Selective, Replication-Competent Adenovirus Vector for Cancer Gene Therapy. Journal of Virology, 2001, 75, 3314-3324. | 1.5 | 113 |
| 10 | Overexpression of the ADP (E3-11.6K) Protein Increases Cell Lysis and Spread of Adenovirus. Virology, 2003, 305, 378-387. | 1.1 | 112 |
| 11 | Immunosuppression Enhances Oncolytic Adenovirus Replication and Antitumor Efficacy in the Syrian Hamster Model. Molecular Therapy, 2008, 16, 1665-1673. | 3.7 | 109 |
| 12 | Inhibition of TRAIL-Induced Apoptosis and Forced Internalization of TRAIL Receptor 1 by Adenovirus Proteins. Journal of Virology, 2001, 75, 8875-8887. | 1.5 | 104 |
| 13 | Specific Recruitment of Î³Î´ Regulatory T Cells in Human Breast Cancer. Cancer Research, 2013, 73, 6137-6148. | 0.4 | 94 |
| 14 | Cotton Rat Tumor Model for the Evaluation of Oncolytic Adenoviruses. Human Gene Therapy, 2005, 16, 139-146. | 1.4 | 62 |
| 15 | Effect of Preexisting Immunity on Oncolytic Adenovirus Vector INGN 007 Antitumor Efficacy in Immunocompetent and Immunosuppressed Syrian Hamsters. Journal of Virology, 2009, 83, 2130-2139. | 1.5 | 57 |
| 16 | Syrian Hamster as an Animal Model to Study Oncolytic Adenoviruses and to Evaluate the Efficacy of Antiviral Compounds. Advances in Cancer Research, 2012, 115, 69-92. | 1.9 | 57 |
| 17 | Oncolytic (replication-competent) adenoviruses as anticancer agents. Expert Opinion on Biological Therapy, 2010, 10, 353-368. | 1.4 | 54 |
| 18 | An Oncolytic Adenovirus Vector Combining Enhanced Cell-to-Cell Spreading, Mediated by the ADP Cytolytic Protein, with Selective Replication in Cancer Cells with Deregulated Wnt Signaling. Cancer Research, 2004, 64, 3638-3644. | 0.4 | 53 |

| # | ARTICLE | IF | CITATIONS |
|---|---|---|---|
| 19 | INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: comparison of biodistribution studies. Cancer Gene Therapy, 2009, 16, 625-637. | 2.2 | 48 |
| 20 | New drug on the horizon for treating adenovirus. Expert Opinion on Pharmacotherapy, 2015, 16, 2095-2099. | 0.9 | 46 |
| 21 | STAT2 Knockout Syrian Hamsters Support Enhanced Replication and Pathogenicity of Human Adenovirus, Revealing an Important Role of Type I Interferon Response in Viral Control. PLoS Pathogens, 2015, 11, e1005084. | 2.1 | 45 |
| 22 | An acute toxicology study with INGN 007, an oncolytic adenovirus vector, in mice and permissive Syrian hamsters; comparisons with wild-type Ad5 and a replication-defective adenovirus vector. Cancer Gene Therapy, 2009, 16, 644-654. | 2.2 | 42 |
| 23 | Increasing the Efficacy of Oncolytic Adenovirus Vectors. Viruses, 2010, 2, 1844-1866. | 1.5 | 42 |
| 24 | Ganciclovir Inhibits Human Adenovirus Replication and Pathogenicity in Permissive Immunosuppressed Syrian Hamsters. Antimicrobial Agents and Chemotherapy, 2014, 58, 7171-7181. | 1.4 | 39 |
| 25 | Cidofovir and brincidofovir reduce the pathology caused by systemic infection with human type 5 adenovirus in immunosuppressed Syrian hamsters, while ribavirin is largely ineffective in this model. Antiviral Research, 2014, 112, 38-46. | 1.9 | 39 |
| 26 | Pre-existing Immunity and Passive Immunity to Adenovirus 5 Prevents Toxicity Caused by an Oncolytic Adenovirus Vector in the Syrian Hamster Model. Molecular Therapy, 2009, 17, 1724-1732. | 3.7 | 38 |
| 27 | Radiation increases the activity of oncolytic adenovirus cancer gene therapy vectors that overexpress the ADP (E3-11.6K) protein. Cancer Gene Therapy, 2003, 10, 193-200. | 2.2 | 37 |
| 28 | Adenovirus E3-6.7K Protein Is Required in Conjunction with the E3-RID Protein Complex for the Internalization and Degradation of TRAIL Receptor 2. Journal of Virology, 2004, 78, 12297-12307. | 1.5 | 28 |
| 29 | New pancreatic carcinoma model for studying oncolytic adenoviruses in the permissive Syrian hamster. Cancer Gene Therapy, 2009, 16, 912-922. | 2.2 | 26 |
| 30 | Drug development against human adenoviruses and its advancement by Syrian hamster models. FEMS Microbiology Reviews, 2019, 43, 380-388. | 3.9 | 26 |
| 31 | Pathology in Permissive Syrian Hamsters after Infection with Species C Human Adenovirus (HAdV-C) Is the Result of Virus Replication: HAdV-C6 Replicates More and Causes More Pathology than HAdV-C5. Journal of Virology, 2017, 91, . | 1.5 | 24 |
| 32 | Characterization of an N-Terminal Non-Core Domain of RAG1 Gene Disrupted Syrian Hamster Model Generated by CRISPR Cas9. Viruses, 2018, 10, 243. | 1.5 | 23 |
| 33 | The role of cyclophosphamide in enhancing antitumor efficacy of an adenovirus oncolytic vector in subcutaneous Syrian hamster tumors. Cancer Gene Therapy, 2013, 20, 521-530. | 2.2 | 21 |
| 34 | Adenovirus replicationâ€“competent vectors (KD1, KD3) complement the cytotoxicity and transgene expression from replication-defective vectors (Ad-GFP, Ad-Luc). Cancer Gene Therapy, 2002, 9, 651-654. | 2.2 | 20 |
| 35 | Valganciclovir Inhibits Human Adenovirus Replication and Pathology in Permissive Immunosuppressed Female and Male Syrian Hamsters. Viruses, 2015, 7, 1409-1428. | 1.5 | 20 |
| 36 | Transcriptome sequencing and development of an expression microarray platform for liver infection in adenovirus type 5-infected Syrian golden hamsters. Virology, 2015, 485, 305-312. | 1.1 | 20 |

| # | ARTICLE | IF | CITATIONS |
|---|---|---|---|
| 37 | USC-087 protects Syrian hamsters against lethal challenge with human species C adenoviruses. Antiviral Research, 2018, 153, 1-9. | 1.9 | 19 |
| 38 | Anti-adenoviral Artificial MicroRNAs Expressed from AAV9 Vectors Inhibit Human Adenovirus Infection in Immunosuppressed Syrian Hamsters. Molecular Therapy - Nucleic Acids, 2017, 8, 300-316. | 2.3 | 18 |
| 39 | Cycles of transient high-dose cyclophosphamide administration and intratumoral oncolytic adenovirus vector injection for long-term tumor suppression in Syrian hamsters. Cancer Gene Therapy, 2014, 21, 171-178. | 2.2 | 16 |
| 40 | A multitasking oncolytic adenovirus vector. Molecular Therapy, 2003, 7, 435-437. | 3.7 | 14 |
| 41 | Syrian Hamster Tumor Model to Study Oncolytic Ad5-Based Vectors. Methods in Molecular Biology, 2012, 797, 53-63. | 0.4 | 14 |
| 42 | Male Syrian hamsters are more susceptible to intravenous infection with species C human adenoviruses than are females. Virology, 2018, 514, 66-78. | 1.1 | 12 |
| 43 | Immunocompetent, Semi-Permissive Cotton Rat Tumor Model for the Evaluation of Oncolytic Adenoviruses. , 2007, 130, 157-168. | | 11 |
| 44 | The effects of radiation on antitumor efficacy of an oncolytic adenovirus vector in the Syrian hamster model. Cancer Gene Therapy, 2013, 20, 531-537. | 2.2 | 11 |
| 45 | Filociclovir Is a PotentIn VitroandIn VivoInhibitor of Human Adenoviruses. Antimicrobial Agents and Chemotherapy, 2020, 64, . | 1.4 | 11 |
| 46 | Adenovirus immunoregulatory E3 proteins prolong transplants of human cells in immunocompetent mice. Virus Research, 2005, 108, 149-159. | 1.1 | 10 |
| 47 | A fully replication-competent adenovirus vector with enhanced oncolytic properties. Cancer Gene Therapy, 2010, 17, 761-770. | 2.2 | 10 |
| 48 | HAdV-C6 Is a More Relevant Challenge Virus than HAdV-C5 for Testing Antiviral Drugs with the Immunosuppressed Syrian Hamster Model. Viruses, 2017, 9, 147. | 1.5 | 9 |
| 49 | Generation and characterization of an IL2RG knockout Syrian hamster model for XSCID and HAdV-C6 infection in immunocompromised patients. DMM Disease Models and Mechanisms, 2020, 13, . | 1.2 | 9 |
| 50 | Construction and Characterization of E1-Minus Replication-Defective Adenovirus Vectors that Express E3 Proteins from the E1 Region. Virology, 2002, 301, 99-108. | 1.1 | 7 |
| 51 | Combination therapy with brincidofovir and valganciclovir against species C adenovirus infection in the immunosuppressed Syrian hamster model allows for substantial reduction of dose for both compounds. Antiviral Research, 2017, 146, 121-129. | 1.9 | 7 |
| 52 | HEK? No!. Molecular Therapy, 2002, 5, 654. | 3.7 | 4 |
| 53 | Adenovirus inhibition of immune-mediated apoptosis. Clinical Immunology Newsletter, 1999, 19, 1-7. | 0.1 | 2 |
| 54 | 642. Toxicological Findings with Oncolytic Adenovirus Vector VRX-007, Wild-Type Ad5, and a Replication-Defective Adenovirus Vector in Syrian Hamsters and C57BL/6 Mice. Molecular Therapy, 2006, 13, S247. | 3.7 | 0 |

| # | ARTICLE | IF | CITATIONS |
|---|---|---|---|
| 55 | 651. VRX-007, an Oncolytic Adenovirus Vector, Replicates in Syrian Hamsters but Not Mice: Comparison of Biodistribution Studies Performed in the Syrian Hamster and Mouse. Molecular Therapy, 2006, 13, S251. | 3.7 | 0 |
| 56 | 16. STAT2 Knockout Syrian Hamsters Support Enhanced Replication and Pathogenicity of Human Adenovirus Type 5, Revealing an Important Role of Type I Interferon Response in Viral Control. Molecular Therapy, 2016, 24, S8. | 3.7 | 0 |
| 57 | Biographical Feature: William S. M. Wold, Ph.D., 1944-2021. Journal of Virology, 2021, 95, e0118421. | 1.5 | 0 |
| 58 | Abstract 130: Regulatory role of miR-29b in prostate cancer metastasis. , 2012, , . | | 0 |